Matches in Wikidata for { <http://www.wikidata.org/entity/Q90925065> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q90925065 description "2020 թվականին հրատարակված գիտական հոդված" @default.
- Q90925065 description "article scientifique (publié 2020)" @default.
- Q90925065 description "articolo scientifico (pubblicato il 2020)" @default.
- Q90925065 description "artigo científico (publicado na 2020)" @default.
- Q90925065 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q90925065 description "artículo científico publicado en 2020" @default.
- Q90925065 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q90925065 description "im Jahr 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90925065 description "scientific article published on 01 January 2020" @default.
- Q90925065 description "wetenschappelijk artikel" @default.
- Q90925065 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q90925065 description "научна статия" @default.
- Q90925065 name "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 name "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 name "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 type Item @default.
- Q90925065 label "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 label "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 label "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 prefLabel "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 prefLabel "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 prefLabel "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 P1433 Q90925065-536A88E8-1656-450E-8937-22773AB1EA4D @default.
- Q90925065 P1476 Q90925065-68C8D54B-0BF0-4750-A8E9-5E3DE7A7885D @default.
- Q90925065 P2093 Q90925065-25114A77-A75E-4B32-9290-3AA24E2D7C24 @default.
- Q90925065 P2093 Q90925065-46A2A362-6258-4EC7-AEF6-19DE1161E9F2 @default.
- Q90925065 P2093 Q90925065-4BD6B8A4-FBF5-4F4D-B171-91A63D82BF12 @default.
- Q90925065 P2093 Q90925065-A0383E12-BD58-4D7A-B2C9-9DECABE648C2 @default.
- Q90925065 P2093 Q90925065-A0C35BA2-FF89-41FB-A0BC-8BD1E86DFC3A @default.
- Q90925065 P2093 Q90925065-C534A7B5-E9B3-4DD5-9C68-E5D0EC28E873 @default.
- Q90925065 P2093 Q90925065-C8647880-023E-4AD9-BC83-CCA2FDA4B776 @default.
- Q90925065 P2093 Q90925065-FAABF2A1-E448-4C3E-91A6-742914A75DD3 @default.
- Q90925065 P304 Q90925065-92716EA3-A993-4C02-BDC6-01FE55852AE4 @default.
- Q90925065 P31 Q90925065-8E9DA033-BE8C-4330-9F7E-C69F48E75F67 @default.
- Q90925065 P356 Q90925065-AD11FBB1-1CD1-4043-9A4F-64413CF9225D @default.
- Q90925065 P433 Q90925065-C1D1572B-E378-4071-8EBB-FC7B49B3F588 @default.
- Q90925065 P478 Q90925065-B75F22B2-9331-416B-B8E1-8AEC4AB75F38 @default.
- Q90925065 P50 Q90925065-135565CC-C06A-419F-ADCF-F781743E28D0 @default.
- Q90925065 P577 Q90925065-45AC4017-4665-4B78-9BC7-697AFFB10ABE @default.
- Q90925065 P698 Q90925065-25EC96F1-CC5B-41D3-B347-FE6D686A4709 @default.
- Q90925065 P921 Q90925065-CCE3CC26-E67F-4AD4-8192-8BFD8311B562 @default.
- Q90925065 P356 IZZ271 @default.
- Q90925065 P698 31648296 @default.
- Q90925065 P1433 Q15749161 @default.
- Q90925065 P1476 "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q90925065 P2093 "Ann Gils" @default.
- Q90925065 P2093 "Annick Moens" @default.
- Q90925065 P2093 "Gert Van Assche" @default.
- Q90925065 P2093 "Griet Compernolle" @default.
- Q90925065 P2093 "Matthias Lenfant" @default.
- Q90925065 P2093 "Michiel Bronswijk" @default.
- Q90925065 P2093 "Sophie Tops" @default.
- Q90925065 P2093 "Séverine Vermeire" @default.
- Q90925065 P304 "161" @default.
- Q90925065 P31 Q13442814 @default.
- Q90925065 P356 "10.1093/IBD/IZZ271" @default.
- Q90925065 P433 "1" @default.
- Q90925065 P478 "26" @default.
- Q90925065 P50 Q110729292 @default.
- Q90925065 P577 "2020-01-01T00:00:00Z" @default.
- Q90925065 P698 "31648296" @default.
- Q90925065 P921 Q323936 @default.